Hughes Hubbard and Macfarlanes advise on $1.2bn sale of Chiltern to LabCorp

31 July 2017

Laboratory Corporation of America Holdings (LabCorp) and Chiltern announced today that they have entered into a definitive agreement under which LabCorp will acquire Chiltern in an all-cash transaction valued at approximately $1.2bn. Upon completion of the transaction, Chiltern will become part of LabCorp’s Covance Drug Development segment.

Hughes, Hubbard & Reed and Macfarlanes advised Chiltern on the transaction. The Hughes Hubbard team was led by corporate partners James Modlin and David Schwartz. The Macfarlanes team was led by corporate partner Stephen Drewitt, supported by senior solicitor Tom Rose.